Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BOLTNASDAQ:CNTBNASDAQ:KNTENYSE:VOR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBOLTBolt Biotherapeutics$6.10+3.2%$6.40$5.20▼$15.60$11.71M0.8911,320 shs928 shsCNTBConnect Biopharma$1.14+5.1%$0.86$0.51▼$1.60$63.06M-0.256,810 shs148,655 shsKNTEKinnate Biopharma$2.65$2.61$1.04▼$7.18$125.13M1.38418,678 shsN/AVORVor Biopharma$1.89+30.0%$0.43$0.13▼$2.04$235.55M2.044.23 million shs24.49 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBOLTBolt Biotherapeutics+3.20%+6.07%+0.48%-15.29%-58.51%CNTBConnect Biopharma+5.09%+16.95%+39.95%+80.16%-12.69%KNTEKinnate Biopharma0.00%0.00%0.00%0.00%0.00%VORVor Biopharma+30.00%+111.80%+750.63%+232.39%+104.89%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBOLTBolt Biotherapeutics3.0448 of 5 stars3.23.00.00.02.81.71.3CNTBConnect Biopharma3.3528 of 5 stars3.55.00.00.01.42.50.6KNTEKinnate BiopharmaN/AN/AN/AN/AN/AN/AN/AN/AVORVor Biopharma4.0201 of 5 stars4.35.00.00.03.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBOLTBolt Biotherapeutics 2.33Hold$50.00719.81% UpsideCNTBConnect Biopharma 3.00Buy$7.00516.74% UpsideKNTEKinnate Biopharma 0.00N/AN/AN/AVORVor Biopharma 2.60Moderate Buy$5.63198.60% UpsideCurrent Analyst Ratings BreakdownLatest VOR, CNTB, BOLT, OXB, and KNTE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/30/2025VORVor BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$3.006/26/2025VORVor BiopharmaWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Outperform6/12/2025CNTBConnect BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$7.005/20/2025BOLTBolt BiotherapeuticsLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$80.005/13/2025BOLTBolt BiotherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$25.00 ➝ $20.005/9/2025VORVor BiopharmaCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/9/2025VORVor BiopharmaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Perform$6.00 ➝ $6.005/9/2025VORVor BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral5/8/2025VORVor BiopharmaJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/8/2025VORVor BiopharmaBaird R WSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/8/2025VORVor BiopharmaWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Neutral$7.00 ➝ $0.40(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBOLTBolt Biotherapeutics$7.69M1.52N/AN/A$29.89 per share0.20CNTBConnect Biopharma$26.03M2.42N/AN/A$1.67 per share0.68KNTEKinnate BiopharmaN/AN/AN/AN/A$5.06 per shareN/AVORVor BiopharmaN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBOLTBolt Biotherapeutics-$63.12M-$33.40N/AN/AN/AN/A-94.51%-59.07%8/12/2025 (Estimated)CNTBConnect Biopharma-$15.63MN/A0.00N/AN/AN/AN/AN/A9/5/2025 (Estimated)KNTEKinnate Biopharma-$116.27M-$2.78N/AN/AN/AN/A-62.31%-54.72%N/AVORVor BiopharmaN/A-$1.51N/AN/AN/AN/AN/AN/AN/ALatest VOR, CNTB, BOLT, OXB, and KNTE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025CNTBConnect Biopharma-$0.26-$0.19+$0.07-$0.19N/AN/A5/12/2025Q1 2025BOLTBolt Biotherapeutics-$6.80-$5.80+$1.00-$0.29$0.77 million$1.22 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBOLTBolt BiotherapeuticsN/AN/AN/AN/AN/ACNTBConnect BiopharmaN/AN/AN/AN/AN/AKNTEKinnate BiopharmaN/AN/AN/AN/AN/AVORVor BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBOLTBolt Biotherapeutics0.483.133.13CNTBConnect Biopharma0.0110.2510.25KNTEKinnate BiopharmaN/A10.8010.80VORVor BiopharmaN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBOLTBolt Biotherapeutics86.70%CNTBConnect Biopharma58.72%KNTEKinnate Biopharma80.89%VORVor Biopharma97.29%Insider OwnershipCompanyInsider OwnershipBOLTBolt Biotherapeutics6.10%CNTBConnect Biopharma22.60%KNTEKinnate Biopharma41.70%VORVor Biopharma2.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBOLTBolt Biotherapeutics901.92 million1.80 millionNot OptionableCNTBConnect Biopharma11055.56 million43.00 millionOptionableKNTEKinnate Biopharma8447.22 million27.53 millionOptionableVORVor Biopharma140124.96 million65.45 millionNot OptionableVOR, CNTB, BOLT, OXB, and KNTE HeadlinesRecent News About These CompaniesHC Wainwright Predicts Weaker Earnings for Vor BiopharmaJuly 4 at 2:35 AM | americanbankingnews.comVor Biopharma Q2 EPS Estimate Decreased by HC WainwrightJuly 2 at 7:41 AM | marketbeat.comHC Wainwright Upgrades Vor Biopharma (NYSE:VOR) to "Buy"July 2 at 2:03 AM | americanbankingnews.comVor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)July 1 at 4:00 PM | globenewswire.comHC Wainwright & Co. Upgrades Vor Biopharma (VOR)June 30, 2025 | msn.comVor Biopharma's RemeGen Deal Paves Way For Multi-Billion Dollar Autoimmune MarketJune 30, 2025 | benzinga.comVor Bio Stock Skyrockets 250% in the Past Week: Here's WhyJune 30, 2025 | zacks.comVor Biopharma (NYSE:VOR) Upgraded at HC WainwrightJune 30, 2025 | marketbeat.comVor Biopharma (NYSE:VOR) Gains Momentum S&P 500June 27, 2025 | kalkinemedia.comKVor Biopharma Inc. Stock Grades - Barron'sJune 27, 2025 | barrons.comVor Biopharma (NYSE:VOR) Stock Price Expected to Rise, Robert W. Baird Analyst SaysJune 27, 2025 | marketbeat.comVor, with new CEO, changes course to target autoimmune diseaseJune 26, 2025 | biopharmadive.comBAfter axing 95% workforce, Vor bets $4B+ on Remegen’s telitaciceptJune 26, 2025 | bioworld.comBVor Biopharma Insider Trading Activity | NASDAQ:VOR | BenzingaJune 26, 2025 | benzinga.comVor Bio's surprise $4B revival deal for RemeGen's autoimmune drug triggers divergent stock reactionsJune 26, 2025 | fiercepharma.comFVor Biopharma Shares Skyrocket on Global Licensing Deal for Autoimmune TherapyJune 26, 2025 | msn.comVor Biopharma Target of Unusually High Options Trading (NYSE:VOR)June 26, 2025 | marketbeat.comVor Biopharma: Vor Bio Announces $175 Million Private PlacementJune 26, 2025 | finanznachrichten.deVor Biopharma: Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune AssetJune 26, 2025 | finanznachrichten.deVor Biopharma stock soars after licensing deal for autoimmune therapyJune 26, 2025 | investing.comWedbush Reaffirms "Neutral" Rating for Vor Biopharma (NYSE:VOR)June 26, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesMore Than a Monetary Metal: Silver's Case for OutperformanceBy Jeffrey Neal Johnson | June 22, 2025View More Than a Monetary Metal: Silver's Case for OutperformanceWhich Analyst-Favorite Drone Stock Will Come Out on Top?By Nathan Reiff | June 25, 2025View Which Analyst-Favorite Drone Stock Will Come Out on Top?Top Steel Picks for the Coming Infrastructure BoomBy Chris Markoch | June 25, 2025View Top Steel Picks for the Coming Infrastructure Boom3 Nuclear ETFs to Watch as U.S. Policy Sparks a SurgeBy Nathan Reiff | June 9, 2025View 3 Nuclear ETFs to Watch as U.S. Policy Sparks a SurgeTop 3 FOMO Stocks for 2025 With More Room to RunBy Dan Schmidt | June 9, 2025View Top 3 FOMO Stocks for 2025 With More Room to RunVOR, CNTB, BOLT, OXB, and KNTE Company DescriptionsBolt Biotherapeutics NASDAQ:BOLT$6.10 +0.19 (+3.20%) Closing price 07/3/2025 01:20 PM EasternExtended Trading$6.10 +0.00 (+0.02%) As of 07/3/2025 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.Connect Biopharma NASDAQ:CNTB$1.14 +0.06 (+5.09%) As of 07/3/2025 03:47 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.Kinnate Biopharma NASDAQ:KNTEKinnate Biopharma Inc., a clinical-stage oncology company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.Vor Biopharma NYSE:VOR$1.88 +0.44 (+30.00%) Closing price 07/3/2025 03:58 PM EasternExtended Trading$1.87 -0.01 (-0.74%) As of 07/3/2025 05:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
